{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:59:15Z","timestamp":1771520355035,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T00:00:00Z","timestamp":1533600000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","award":["2013_A284"],"award-info":[{"award-number":["2013_A284"]}],"id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Deutsche Krebshilfe e.V.","award":["110886"],"award-info":[{"award-number":["110886"]}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG EXC1003"],"award-info":[{"award-number":["DFG EXC1003"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.tranon.2018.08.004","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T11:02:54Z","timestamp":1534503774000},"page":"1271-1282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma"],"prefix":"10.1016","volume":"11","author":[{"given":"Torsten","family":"Kessler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Baumeier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Brand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Grau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2502-9910","authenticated-orcid":false,"given":"Linus","family":"Angenendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saliha","family":"Harrach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Stalmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Henning","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Gosheger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jendrik","family":"Hardes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5083-9678","authenticated-orcid":false,"given":"Dimosthenis","family":"Andreou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Dreischal\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-4910","authenticated-orcid":false,"given":"Eva","family":"Wardelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf M.","family":"Mesters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Schw\u00f6ppe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2018.08.004_bb0005","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.ejca.2012.09.011","article-title":"Epidemiology of sarcomas in Europe: report from the RARECARE project","volume":"49","author":"Stiller","year":"2013","journal-title":"Eur J Cancer"},{"issue":"Suppl. 3","key":"10.1016\/j.tranon.2018.08.004_bb0010","first-page":"iii102","article-title":"Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","author":"The ESMO\/European Sarcoma Network Working Group","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tranon.2018.08.004_bb0015","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/JCO.2015.62.4734","article-title":"Efficacy and safety of trabectidin or dacarbazine for metastatic liposarcoma or leiomyosarcoma after failure of conventional chemotherapy: results of a phase III randomized multicentre trial","volume":"34","author":"Demetri","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tranon.2018.08.004_bb0020","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft tissue sarcoma (PALETTE): a randomized, double blind, placebo-controlled phase III trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2018.08.004_bb0025","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Erubilin versus dacarbazine in previously treated patients with advanced liposarcoma and leiomyosarcoma: a randomized, open label, multicentre, phase III trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2018.08.004_bb0030","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomized phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2018.08.004_bb0035","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2018.08.004_bb0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/bjc.1982.16","article-title":"Endothelial cell proliferation as a novel approach to targeting tumour therapy","volume":"45","author":"Denekamp","year":"1982","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tranon.2018.08.004_bb0045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1126\/science.275.5299.547","article-title":"Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature","volume":"275","author":"Huang","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.tranon.2018.08.004_bb0050","first-page":"722","article-title":"Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis","volume":"60","author":"Pasqualini","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.tranon.2018.08.004_bb0055","first-page":"867","article-title":"Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells","volume":"62","author":"Curnis","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.tranon.2018.08.004_bb0060","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1349-7006.2010.01826.x","article-title":"Aminopeptidase N (CD13) as a target for cancer chemotherapy","volume":"102","author":"Wickstr\u00f6m","year":"2011","journal-title":"Cancer Sci"},{"key":"10.1016\/j.tranon.2018.08.004_bb0065","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1073\/pnas.1120790109","article-title":"Cooperative effects of aminopeptidase N (CD13) expressed by nonmalignant and cancer cells within the tumor microenvironment","volume":"109","author":"Guzman-Rojas","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tranon.2018.08.004_bb0070","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1158\/1078-0432.CCR-06-0338","article-title":"Clinical significance of aminopeptidase N in non\u2013small cell lung cancer","volume":"12","author":"Tokuhara","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2018.08.004_bb0075","first-page":"1503","article-title":"Clinical significance of aminopeptidase N\/CD13 expression in human pancreatic carcinoma","volume":"9","author":"Ikeda","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2018.08.004_bb0080","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/gast.2002.31095","article-title":"Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer","volume":"122","author":"Hashida","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tranon.2018.08.004_bb0085","article-title":"Potential therapeutic impact of CD13 expression in non-small cell lung cancer","volume":"12","author":"Schmidt","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2018.08.004_bb0090","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1136\/ijgc-00009577-200609000-00010","article-title":"Expression of aminopeptidase N\/CD13 in human ovarian cancers","volume":"16","author":"Surowiak","year":"2006","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.tranon.2018.08.004_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/157016308783769487","article-title":"Generation of fusion proteins for selective occlusion of tumor vessels","volume":"5","author":"Kessler","year":"2008","journal-title":"Curr Drug Discov Technol"},{"key":"10.1016\/j.tranon.2018.08.004_bb0100","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2008-04-150318","article-title":"Infarction of tumor vessels by NGR-peptide-directed targeting of tissue factor: experimental results and first-in man experience","volume":"113","author":"Bieker","year":"2009","journal-title":"Blood"},{"issue":"Suppl. 2","key":"10.1016\/j.tranon.2018.08.004_bb0105","doi-asserted-by":"crossref","first-page":"S143","DOI":"10.1016\/S0049-3848(10)70033-5","article-title":"Tissue-factor fusion proteins induce occlusion of tumor vessels","volume":"125","author":"Schw\u00f6ppe","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.tranon.2018.08.004_bb0110","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1021\/jm301669z","article-title":"Anticancer therapy by tumor vessel infarction with polyethylene glycol conjugated retargeted tissue factor","volume":"56","author":"Schw\u00f6ppe","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.tranon.2018.08.004_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10456-013-9391-4","article-title":"Non-invasive monitoring of tumor-vessel infarction by retargeted truncated tissue factor tTF-NGR using multi-modal imaging","volume":"17","author":"Persigehl","year":"2014","journal-title":"Angiogenesis"},{"key":"10.1016\/j.tranon.2018.08.004_bb0120","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1021\/acs.molpharmaceut.5b00508","article-title":"Tumor growth inhibition via occlusion of tumor vasculature induced by N-terminally PEGylated retargeted tissue factor tTF-NGR","volume":"12","author":"Brand","year":"2015","journal-title":"Mol Pharm"},{"key":"10.1016\/j.tranon.2018.08.004_bb0125","doi-asserted-by":"crossref","first-page":"82458","DOI":"10.18632\/oncotarget.12559","article-title":"Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction","volume":"7","author":"Stucke-Ring","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2018.08.004_bb0130","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3892\/ijo.2013.1940","article-title":"Identification of APN\/CD13 as a target antigen for FU3, a human monoclonal antibody that recognizes malignant fibrous histiocytoma","volume":"43","author":"Aoki","year":"2013","journal-title":"Int J Oncol"},{"issue":"7","key":"10.1016\/j.tranon.2018.08.004_bb0135","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1023\/A:1027383729767","article-title":"Inhibitory effect of antisense aminopeptidase N (APN\/CD13) cDNA transfection on the invasive potential of osteosarcoma cells","volume":"20","author":"Kido","year":"2003","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.tranon.2018.08.004_bb0140","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.3892\/ijo.2014.2664","article-title":"Possible contribution of aminopeptidase N (APN\/CD13) to migration and invasion of human osteosarcoma cell lines","volume":"45","author":"Liang","year":"2014","journal-title":"Int J Oncol"},{"key":"10.1016\/j.tranon.2018.08.004_bb0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.lungcan.2017.09.013","article-title":"CD13 as target for tissue factor induced tumor vascular infarction in small cell lung cancer","volume":"113","author":"Schmidt","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2018.08.004_bb0150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1046\/j.1440-1827.2001.01162.x","article-title":"Quantitative immunohistochemical evaluation of HER2\/neu expression with HercepTestTM in breast carcinoma by image analysis","volume":"51","author":"Hatanaka","year":"2001","journal-title":"Pathol Int"},{"key":"10.1016\/j.tranon.2018.08.004_bb0155","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197315","article-title":"Adjuvant chemotherapy-radiotherapy-chemotherapy sandwich protocol in resectable soft tissue sarcoma: an updated single-center analysis of 104 cases","volume":"13","author":"Schliemann","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tranon.2018.08.004_bb0160","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomized controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.tranon.2018.08.004_bb0170","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1182\/blood.V97.3.652","article-title":"CD13\/APN is activated by angiogenic signals and is essential for capillary tube formation","volume":"97","author":"Bhagwat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2018.08.004_bb0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.apradiso.2013.12.035","article-title":"Radiolabeled NGR phage display peptide sequence for tumor targeting","volume":"86","author":"Faintuch","year":"2014","journal-title":"Appl Radiat Isot"},{"key":"10.1016\/j.tranon.2018.08.004_bb0180","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jlcr.3260","article-title":"Synthesis and evaluation of novel Tc-99m labeled NGR-containig hexapeptides as tumor imaging agents","volume":"58","author":"Kim","year":"2015","journal-title":"J Label Compd Radiopharm"},{"key":"10.1016\/j.tranon.2018.08.004_bb0185","doi-asserted-by":"crossref","first-page":"3938","DOI":"10.1021\/mp500354x","article-title":"MicroPET imaging of CD13 expression using a 64Cu-labeled dimeric NGR peptide based on sacophagine cage","volume":"11","author":"Li","year":"2014","journal-title":"Mol Pharm"},{"key":"10.1016\/j.tranon.2018.08.004_bb0190","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1007\/s00726-014-1828-6","article-title":"In vivo NIRF imaging-guided delivery of a novel NGR-VEGI fusion protein for targeting tumor vasculature","volume":"46","author":"Ma","year":"2014","journal-title":"Amino Acids"},{"key":"10.1016\/j.tranon.2018.08.004_bb0195","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejps.2015.01.002","article-title":"In vivo imaging of aminopeptidase N (CD13) receptors in experimental renal tumors using the novel radiotracer 68Ga-NOTA-c(NGR)","volume":"69","author":"Mate","year":"2015","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.tranon.2018.08.004_bb0200","doi-asserted-by":"crossref","first-page":"7676","DOI":"10.1158\/0008-5472.CAN-08-0689","article-title":"Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots","volume":"68","author":"Oostendorp","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.tranon.2018.08.004_bb0205","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1007\/s00726-014-1788-x","article-title":"A direct comparison of tumor angiogenesis with 68Ga-labeled NGR and RGD peptides in HT-1080 tumor xenografts using microPET imaging","volume":"46","author":"Shao","year":"2014","journal-title":"Amino Acids"},{"key":"10.1016\/j.tranon.2018.08.004_bb0210","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1016\/j.biomaterials.2014.03.042","article-title":"A tumor-targeting near-infrared laser-triggered drug delivery system based on GO@Ag nanoparticles for chemo-photothermal therapy and x-ray imaging","volume":"35","author":"Shi","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.tranon.2018.08.004_bb0215","doi-asserted-by":"crossref","DOI":"10.1117\/1.2839046","article-title":"In vivo optical imaging of CD13\/APN-expression in tumor xenografts","volume":"13","author":"von Wallbrunn","year":"2008","journal-title":"J Biomed Opt"},{"key":"10.1016\/j.tranon.2018.08.004_bb0220","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.nucmedbio.2013.12.008","article-title":"68Ga-DOTA-NGR as a novel molecular probe for APN-positive tumor imaging using MicroPET","volume":"41","author":"Zhang","year":"2014","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.tranon.2018.08.004_bb0225","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1016\/j.bmcl.2013.07.046","article-title":"Evaluation of 99mTc-probestin for imaging APN expressing tumors by SPECT","volume":"23","author":"Pathuri","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.tranon.2018.08.004_bb0230","first-page":"1215","article-title":"Expression of aminopeptidase N (CD13) in mesenchymal tumors","volume":"137","author":"Mechtersheimer","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1016\/j.tranon.2018.08.004_bb0235","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0959-8049(02)00094-1","article-title":"Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours","volume":"38","author":"Vermeulen","year":"2002","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tranon.2018.08.004_bb0240","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1158\/1078-0432.CCR-04-0969","article-title":"Prognostic significance of increased angiogenesis in osteosarcoma","volume":"10","author":"Kreuter","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2018.08.004_bb0245","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ejca.2006.01.063","article-title":"Clinical significance of vascular endothelial growth factor-A expression in Ewing's sarcoma","volume":"42","author":"Kreuter","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tranon.2018.08.004_bb0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","article-title":"Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs","volume":"21","author":"Van der Veldt","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.tranon.2018.08.004_bb0255","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1054\/bjoc.2001.1837","article-title":"Concentration of vascular endothelial growth factor in the tumor tissue as a prognostic factor of soft tissue sarcomas","volume":"84","author":"Yudoh","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.tranon.2018.08.004_bb0260","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20140075","article-title":"The angiogenic asset of soft tissue sarcomas: a new tool to discover new therapeutic targets","volume":"34","author":"Rocchi","year":"2014","journal-title":"Biosci Rep"},{"key":"10.1016\/j.tranon.2018.08.004_bb0265","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40259-013-0048-z","article-title":"Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example","volume":"27","author":"Corti","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.tranon.2018.08.004_bb0270","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2009.27.3649","article-title":"Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma","volume":"28","author":"Gregorc","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tranon.2018.08.004_bb0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/med.20044","article-title":"Aminopeptidase-N\/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects","volume":"26","author":"Bauvois","year":"2006","journal-title":"Med Res Rev"},{"key":"10.1016\/j.tranon.2018.08.004_bb0280","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/jnci\/95.8.605","article-title":"Randomized double-blind placebo controlled trial of bestatin in patients with resected stage I squamous-cell cancer","volume":"95","author":"Ichinose","year":"2003","journal-title":"J Natl Cancer Inst"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523318303760?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523318303760?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:34:39Z","timestamp":1761834879000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523318303760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1936523318303760"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2018.08.004","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aminopeptidase N (CD13): Expression, Prognostic Impact, and Use as Therapeutic Target for Tissue Factor Induced Tumor Vascular Infarction in Soft Tissue Sarcoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2018.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc.","name":"copyright","label":"Copyright"}]}}